These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11239376)

  • 1. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
    Ando J; Kakishita M; Sakai K; Komura Y; Nishiyama K; Iwabuchi M; Yokoi H; Yasumoto H; Nosaka H; Nobuyoshi M
    Int Heart J; 2005 Jul; 46(4):647-56. PubMed ID: 16157956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
    Shiga T; Matsuda N; Fuda Y; Haruta S; Hagiwara N; Kasanuki H
    J Cardiol; 2002 Mar; 39(3):159-64. PubMed ID: 11912950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias.
    Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y
    Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia.
    Igawa M; Aonuma K; Okamoto Y; Hiroe M; Hiraoka M; Isobe M
    J Cardiovasc Pharmacol; 2002 Nov; 40(5):735-42. PubMed ID: 12409982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
    Takenaka K; Yasuda S; Miyazaki S; Kurita T; Sutani Y; Morii I; Daikoku S; Kamakura S; Nonogi H
    Jpn Circ J; 2001 Jan; 65(1):60-2. PubMed ID: 11153825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys.
    Ishizaka T; Yoshimatsu Y; Maeda Y; Chiba K; Mori K
    Exp Anim; 2019 Feb; 68(1):91-102. PubMed ID: 30333366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.
    Yusu S; Ikeda T; Mera H; Miyakoshi M; Miwa Y; Abe A; Tsukada T; Ishiguro H; Shimizu H; Yoshino H
    Circ J; 2009 Nov; 73(11):2021-8. PubMed ID: 19724153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.
    Watanabe H; Chinushi M; Washizuka T; Sugiura H; Hirono T; Aizawa Y; Komura S; Hosaka Y; Tanabe Y; Furushima H; Aizawa Y
    Circ J; 2006 May; 70(5):583-7. PubMed ID: 16636494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifekalant hydrochloride terminated electrical storms after coronary surgery.
    Kurisu K; Hisahara M; Onitsuka H; Sekiya M; Ikeuchi M; Kozai T; Urabe Y
    Ann Thorac Surg; 2010 May; 89(5):1637-9. PubMed ID: 20417798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of destabilization and early termination of spiral wave reentry in the ventricle by a class III antiarrhythmic agent, nifekalant.
    Yamazaki M; Honjo H; Nakagawa H; Ishiguro YS; Okuno Y; Amino M; Sakuma I; Kamiya K; Kodama I
    Am J Physiol Heart Circ Physiol; 2007 Jan; 292(1):H539-48. PubMed ID: 16936005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
    Myoishi M; Yasuda S; Miyazaki S; Ueno K; Morii I; Satomi K; Otsuka Y; Kawamura A; Kurita T; Kamakura S; Nonogi H
    Circ J; 2003 Oct; 67(10):898-900. PubMed ID: 14578629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation.
    Katoh T; Mitamura H; Matsuda N; Takano T; Ogawa S; Kasanuki H
    Circ J; 2005 Oct; 69(10):1237-43. PubMed ID: 16195624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
    Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic actions of growth hormone during acute myocardial infarction.
    Elaiopoulos DA; Kolettis TM
    J Electrocardiol; 2009; 42(3):298-9. PubMed ID: 19100564
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation.
    Kokaji K; Okamoto M; Hotoda K; Kumamaru H
    Jpn Heart J; 2004 Jul; 45(4):691-5. PubMed ID: 15353881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation.
    Wang J; Hua W; Zhu J; Yang YM; Wang FZ; Pu JL; Chen KP; Zhang S
    Chin Med J (Engl); 2010 Aug; 123(15):2028-33. PubMed ID: 20819537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.